000 01447 a2200433 4500
005 20250515140102.0
264 0 _c20090107
008 200901s 0 0 eng d
022 _a1096-8652
024 7 _a10.1002/ajh.21280
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aWeinreb, Neal
245 0 0 _aA benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
_h[electronic resource]
260 _bAmerican journal of hematology
_cDec 2008
300 _a890-5 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdolescent
650 0 4 _aAdult
650 0 4 _aChild
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aFemale
650 0 4 _aGaucher Disease
_xdrug therapy
650 0 4 _aGenotype
650 0 4 _aGlucosylceramidase
_xadministration & dosage
650 0 4 _aHumans
650 0 4 _aLongitudinal Studies
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aRecombinant Proteins
_xadministration & dosage
650 0 4 _aRegistries
650 0 4 _aRetrospective Studies
650 0 4 _aYoung Adult
700 1 _aTaylor, John
700 1 _aCox, Timothy
700 1 _aYee, John
700 1 _avom Dahl, Stephan
773 0 _tAmerican journal of hematology
_gvol. 83
_gno. 12
_gp. 890-5
856 4 0 _uhttps://doi.org/10.1002/ajh.21280
_zAvailable from publisher's website
999 _c18286108
_d18286108